Basit öğe kaydını göster

dc.contributor.authorSuer, Kaya
dc.contributor.authorTulek, Necla Eren
dc.contributor.authorTutuncu, Emin Ediz
dc.contributor.authorKoruk, Suda Tekin
dc.contributor.authorAYGEN, BİLGEHAN
dc.contributor.authorDEMİRTÜRK, NEŞE
dc.contributor.authorKinikli, Sami
dc.contributor.authorKaya, Ali
dc.contributor.authorYildirmak, Taner
dc.contributor.authorKorkmaz, Fatime
dc.contributor.authorURAL, ONUR
dc.contributor.authorAKHAN, SILA
dc.contributor.authorGÜNAL, ÖZGÜR
dc.contributor.authorTuna, Nazan
dc.contributor.authorKose, Sukran
dc.contributor.authorGonen, Ibak
dc.contributor.authorBatirel, Ayse
dc.contributor.authorTuncer, Gunay
dc.contributor.authorTosun, Dervis
dc.contributor.authorŞENER, ALPER
dc.contributor.authorAynioglu, Aynur
dc.contributor.authorAltunok, Elif Sargin
dc.contributor.authorOrmen, Bahar
dc.contributor.authorTurker, Nesrin
dc.contributor.authorSaltoglu, Nese
dc.contributor.authorBulut, Cemal
dc.contributor.authorSIRMATEL, FATMA
dc.contributor.authorUlcay, Asim
dc.contributor.authorKaragoz, Ergenekon
dc.contributor.authorGurbuz, Yunus
dc.date.accessioned2021-03-06T07:21:36Z
dc.date.available2021-03-06T07:21:36Z
dc.date.issued2016
dc.identifier.citationGurbuz Y., Tulek N. E. , Tutuncu E. E. , Koruk S. T. , AYGEN B., DEMİRTÜRK N., Kinikli S., Kaya A., Yildirmak T., Suer K., et al., "Evaluation of Dual Therapy in Real Life Setting in Treatment-Naive Turkish Patients with HCV Infection: A Multicenter, Retrospective Study", BALKAN MEDICAL JOURNAL, cilt.33, ss.18-26, 2016
dc.identifier.issn2146-3123
dc.identifier.otherav_dc4aa1d8-cbd2-46f2-80c0-69c42cad3000
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/145196
dc.identifier.urihttps://doi.org/10.5152/balkanmedj.2015.15859
dc.description.abstractBackground: Before the introduction of direct-acting antivirals in the treatment of chronic hepatitis C patients, the combination of peginterferon alpha and ribavirin was the standard therapy. Observational studies that investigated sustained virological response (SVR) rates by these drugs yielded different outcomes.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleEvaluation of Dual Therapy in Real Life Setting in Treatment-Naive Turkish Patients with HCV Infection: A Multicenter, Retrospective Study
dc.typeMakale
dc.relation.journalBALKAN MEDICAL JOURNAL
dc.contributor.departmentDiskapi Yildirim Beyazit Training & Research Hospital , ,
dc.identifier.volume33
dc.identifier.issue1
dc.identifier.startpage18
dc.identifier.endpage26
dc.contributor.firstauthorID229597


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster